COBE REVOLUTION CENTRIFUGAL BLOOD PUMP WITH PC, MODEL 050300700

{0}------------------------------------------------ K030462 # SPECIAL 510(K) NOTIFICATION Cobe Cardiovascular Inc. Revolution® Centrifugal Blood Pump with PC Coating | IX. | 510(k) SUMMARY | MAR 0 6 2003 | |-----|----------------|--------------| |-----|----------------|--------------| | SUBMITTER: | COBE Cardiovascular, Inc.<br>14401 West 65th Way<br>Arvada, CO 80004 USA | |-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------| | CONTACT PERSON: | Charles Copperberg<br>Senior Manager, Regulatory and Clinical Affairs<br>Charlie.Copperberg@cobecv.com<br>Phone: (303) 467-6521<br>Fax: (303) 467-6525 | | DATE PREPARED: | February 10, 2003 | | DEVICE TRADE<br>NAME: | COBE Cardiovascular Revolution ^®<br>Centrifugal Blood Pump with PC Coating | | COMMON/USUAL<br>NAME: | Centrifugal Blood Pump | | CLASSIFICATION<br>NAME: | Nonroller-type cardiopulmonary bypass blood pump | | PREDICATE<br>DEVICE: | COBE Cardiovascular Revolution Centrifugal Blood Pump<br>K011835 | | | Dideco Monolyth Mimesys Hollow Fiber Oxygenator<br>K004001 | | | Dideco Avant PH.I.S.I.O. Hollow Fiber Oxygenator<br>K020351 | ## DEVICE DESCRIPTION: The Cobe Cardiovascular Revolution Pump with PC Coating is an extracorporeal blood pump that is provided sterile, single use only, with non-pyrogenic fluid pathways, and is not to be resterilized by the user. It may be sold as a stand-alone device or as a component of a customized heart/lung pack. The Revolution Centrifugal Blood Pump with PC Coating utilizes a rotating, vaned impeller design to move blood by centrifugal force. Blood contact surfaces of the PC coated Revolution have been coated with phosphorylcholine to improve blood compatibility, resulting in reduced platelet adhesion on the coated surfaces. {1}------------------------------------------------ ## SPECIAL 510(K) NOTIFICATION Cobe Cardiovascular Inc. Revolution® Centrifugal Blood Pump with PC Coating ## INDICATIONS FOR USE: The pump is intended for use only with Stöckert Instrumente Centrifugal Pump Consoles in cardiopulmonary bypass procedures for periods of up to six hours. Refer to the console operator's manual for console operating procedures. The pump has not been qualified through in vitro, in vivo, or clinical studies for long term use (i.e., longer than six hours) as a bridge to transplant, for pending recovery of the natural heart or extracorporeal membrane oxygenation (ECMO). ### STATEMENT OF TECHNICAL CHARACTERISTICS COMPARISON: The Revolution Centrifugal Blood Pump with PC coating has the same intended use as the current Revolution Centrifugal Blood Pump. The two devices differ in that the blood contacting surfaces of the Revolution with PC coating have been treated with phosphorylcholine. Otherwise, materials, components, design, sterilization and manufacturing processes for the two devices are the same. ### TESTING TO DETERMINE SUBSTANTIAL EQUIVALENCE: In-Vitro laboratory tests were performed to demonstrate that the Revolution Centrifugal Blood Pump with PC Coating described in this submission is substantially equivalent to the Revolution Centrifugal Blood Pump (K011835). {2}------------------------------------------------ Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 MAR 0 6 2003 COBE Cardiovascular, Inc. c/o Mr. Charles Copperberg Senior Manager, Regulatory and Clinical Affairs 14401 West 65" Way Arvada, CO 80004 Re: K030462 Trade Name: COBE Cardiovascular Revolution® Centrifugal Blood Pump with PC Coating. Regulation Number: 21 CFR 870.4360 Regulation Name: Nonroller-type Cardiopulmonary Bypass Blood Pump Regulatory Class: Class III (three) Product Code: KFM Dated: February 11, 2003 Received: February 12, 2003 Dear Mr. Copperberg: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ Page 2 - Mr. Charles Copperberg. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If vou desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Qelll lll Bram D. Zuckerman. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ #### Indications For Use 510(k) Number (if known): K030462 Device Name: COBE Cardiovascular Revolution™ Centrifugal Blood Pump with PC Coating Indications For Use: The pump is intended for use only with Stöckert Instrumente Centrifugal Pump Consoles in cardiopulmonary bypass procedures for periods of up to six hours. Refer to the console operator's manual for console operating procedures. The pump has not been qualified through in vitro, in vivo, or clinical studies for long term use (i.e., longer than six hours) as a bridge to transplant, for pending recovery of the natural heart or extracorporeal membrane oxygenation (ECMO). PLEASE DO NO WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of Cardiovascular Devices 510(k) Number K030462 Prescription Use (Per 21 CFR 801.109) OR Over-The-Counter Use